Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Dec;81(7):1174–1181. doi: 10.1038/sj.bjc.6690826

Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells

K K Dhar 1,3, K Branigan 1, J Parkes 2, R E J Howells 3, P Hand 4, C Musgrove 4, R C Strange 1, A A Fryer 1, C W E Redman 3, P R Hoban 1
PMCID: PMC2374327  PMID: 10584879

Abstract

The expression of cyclin D1 protein in tumour sections from 81 patients with epithelial ovarian cancer was analysed using immunohistochemistry. The tumours that overexpressed cyclin D1 in more than 10% of neoplastic cells were considered positive. Thus overexpression of cyclin D1 was observed in 72/81 (89%) of the cases examined. Protein was detected in both the nucleus and the cytoplasm in 24/81 (30%) and localized exclusively in the cytoplasm in 48/81 (59%) of the tumours. Cyclin D1 was overexpressed in both borderline and invasive tumours. There was no association between protein overexpression and tumour stage and differentiation. Furthermore, no correlation between cyclin D1 expression and clinical outcome was observed. However, in tumours overexpressing cyclin D1 (n = 72), the proportion displaying exclusively cytoplasmic localization of protein was higher in those with serous compared with non-serous histology (P = 0.004, odds ratio 4.8, 95% confidence interval 1.4–19.1). Western analysis using a monoclonal antibody to cyclin D1 identified a 36 kDa protein in homogenates from seven tumours displaying cytoplasmic only and one tumour demonstrating both nuclear and cytoplasmic immunostaining. Using restriction fragment length polymorphism polymerase chain reaction and PCR-multiplex analysis, amplification of the cyclin D1 gene (CCNDI) was detected in 1/29 of the tumours demonstrating overexpression of cyclin D1 protein. We conclude that deregulation of CCND1 expression leading to both cytoplasmic and nuclear protein localization is a frequent event in ovarian cancer and occurs mainly in the absence of gene amplification. © 1999 Cancer Research Campaign

Keywords: ovarian cancer, cyclin D1, cytoplasm: nucleus, amplification, clinical outcome

Full Text

The Full Text of this article is available as a PDF (318.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbieri F., Cagnoli M., Ragni N., Pedullà F., Foglia G., Alama A. Expression of cyclin D1 correlates with malignancy in human ovarian tumours. Br J Cancer. 1997;75(9):1263–1268. doi: 10.1038/bjc.1997.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bellacosa A., Almadori G., Cavallo S., Cadoni G., Galli J., Ferrandina G., Scambia G., Neri G. Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications. Clin Cancer Res. 1996 Jan;2(1):175–180. [PubMed] [Google Scholar]
  3. Betticher D. C., Heighway J., Hasleton P. S., Altermatt H. J., Ryder W. D., Cerny T., Thatcher N. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer. 1996 Feb;73(3):294–300. doi: 10.1038/bjc.1996.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Betticher D. C., Thatcher N., Altermatt H. J., Hoban P., Ryder W. D., Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995 Sep 7;11(5):1005–1011. [PubMed] [Google Scholar]
  5. Bringuier P. P., Tamimi Y., Schuuring E., Schalken J. Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification. Oncogene. 1996 Apr 18;12(8):1747–1753. [PubMed] [Google Scholar]
  6. Callender T., el-Naggar A. K., Lee M. S., Frankenthaler R., Luna M. A., Batsakis J. G. PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer. 1994 Jul 1;74(1):152–158. doi: 10.1002/1097-0142(19940701)74:1<152::aid-cncr2820740124>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  7. Courjal F., Louason G., Speiser P., Katsaros D., Zeillinger R., Theillet C. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer. 1996 Aug 22;69(4):247–253. doi: 10.1002/(SICI)1097-0215(19960822)69:4<247::AID-IJC1>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
  8. Diehl J. A., Sherr C. J. A dominant-negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase 4 (CDK4) and its phosphorylation by CDK-activating kinase. Mol Cell Biol. 1997 Dec;17(12):7362–7374. doi: 10.1128/mcb.17.12.7362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dulić V., Drullinger L. F., Lees E., Reed S. I., Stein G. H. Altered regulation of G1 cyclins in senescent human diploid fibroblasts: accumulation of inactive cyclin E-Cdk2 and cyclin D1-Cdk2 complexes. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11034–11038. doi: 10.1073/pnas.90.23.11034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Foulkes W. D., Campbell I. G., Stamp G. W., Trowsdale J. Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer. Br J Cancer. 1993 Feb;67(2):268–273. doi: 10.1038/bjc.1993.51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gabra H., Watson J. E., Taylor K. J., Mackay J., Leonard R. C., Steel C. M., Porteous D. J., Smyth J. F. Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res. 1996 Mar 1;56(5):950–954. [PubMed] [Google Scholar]
  12. Gansauge S., Gansauge F., Ramadani M., Stobbe H., Rau B., Harada N., Beger H. G. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res. 1997 May 1;57(9):1634–1637. [PubMed] [Google Scholar]
  13. Gillett C., Fantl V., Smith R., Fisher C., Bartek J., Dickson C., Barnes D., Peters G. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 1994 Apr 1;54(7):1812–1817. [PubMed] [Google Scholar]
  14. Gillett C., Smith P., Gregory W., Richards M., Millis R., Peters G., Barnes D. Cyclin D1 and prognosis in human breast cancer. Int J Cancer. 1996 Apr 22;69(2):92–99. doi: 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  15. Howells R. E., Redman C. W., Dhar K. K., Sarhanis P., Musgrove C., Jones P. W., Alldersea J., Fryer A. A., Hoban P. R., Strange R. C. Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer. Clin Cancer Res. 1998 Oct;4(10):2439–2445. [PubMed] [Google Scholar]
  16. Hung W. C., Chai C. Y., Huang J. S., Chuang L. Y. Expression of cyclin D1 and c-Ki-ras gene product in human epithelial ovarian tumors. Hum Pathol. 1996 Dec;27(12):1324–1328. doi: 10.1016/s0046-8177(96)90345-7. [DOI] [PubMed] [Google Scholar]
  17. Kotelnikov V. M., Coon J. S., 4th, Mundle S., Kelanic S., LaFollette S., Taylor S I. V., Hutchinson J., Panje W., Caldarelli D. D., Preisler H. D. Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis. Clin Cancer Res. 1997 Jan;3(1):95–101. [PubMed] [Google Scholar]
  18. Kranenburg O., van der Eb A. J., Zantema A. Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO J. 1996 Jan 2;15(1):46–54. [PMC free article] [PubMed] [Google Scholar]
  19. Kurzrock R., Ku S., Talpaz M. Abnormalities in the PRAD1 (CYCLIN D1/BCL-1) oncogene are frequent in cervical and vulvar squamous cell carcinoma cell lines. Cancer. 1995 Jan 15;75(2):584–590. doi: 10.1002/1097-0142(19950115)75:2<584::aid-cncr2820750223>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  20. Kwon T. K., Buchholz M. A., Gabrielson E. W., Nordin A. A. A novel cytoplasmic substrate for cdk4 and cdk6 in normal and malignant epithelial derived cells. Oncogene. 1995 Nov 16;11(10):2077–2083. [PubMed] [Google Scholar]
  21. LaBaer J., Garrett M. D., Stevenson L. F., Slingerland J. M., Sandhu C., Chou H. S., Fattaey A., Harlow E. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997 Apr 1;11(7):847–862. doi: 10.1101/gad.11.7.847. [DOI] [PubMed] [Google Scholar]
  22. Lucibello F. C., Sewing A., Brüsselbach S., Bürger C., Müller R. Deregulation of cyclins D1 and E and suppression of cdk2 and cdk4 in senescent human fibroblasts. J Cell Sci. 1993 May;105(Pt 1):123–133. doi: 10.1242/jcs.105.1.123. [DOI] [PubMed] [Google Scholar]
  23. Lukas J., Bartkova J., Welcker M., Petersen O. W., Peters G., Strauss M., Bartek J. Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types. Oncogene. 1995 Jun 1;10(11):2125–2134. [PubMed] [Google Scholar]
  24. Masciullo V., Scambia G., Marone M., Giannitelli C., Ferrandina G., Bellacosa A., Benedetti Panici P., Mancuso S. Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas. Int J Cancer. 1997 Aug 22;74(4):390–395. doi: 10.1002/(sici)1097-0215(19970822)74:4<390::aid-ijc5>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  25. Michalides R., van Veelen N., Hart A., Loftus B., Wientjens E., Balm A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res. 1995 Mar 1;55(5):975–978. [PubMed] [Google Scholar]
  26. Motokura T., Bloom T., Kim H. G., Jüppner H., Ruderman J. V., Kronenberg H. M., Arnold A. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature. 1991 Apr 11;350(6318):512–515. doi: 10.1038/350512a0. [DOI] [PubMed] [Google Scholar]
  27. Musgrove E. A., Lee C. S., Buckley M. F., Sutherland R. L. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8022–8026. doi: 10.1073/pnas.91.17.8022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Nishida N., Fukuda Y., Komeda T., Kita R., Sando T., Furukawa M., Amenomori M., Shibagaki I., Nakao K., Ikenaga M. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res. 1994 Jun 15;54(12):3107–3110. [PubMed] [Google Scholar]
  29. Non-surgical aspects of ovarian cancer. Lancet. 1994 Feb 5;343(8893):335–340. [PubMed] [Google Scholar]
  30. Palmero I., Peters G. Perturbation of cell cycle regulators in human cancer. Cancer Surv. 1996;27:351–367. [PubMed] [Google Scholar]
  31. Quelle D. E., Ashmun R. A., Shurtleff S. A., Kato J. Y., Bar-Sagi D., Roussel M. F., Sherr C. J. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev. 1993 Aug;7(8):1559–1571. doi: 10.1101/gad.7.8.1559. [DOI] [PubMed] [Google Scholar]
  32. Sawa H., Ohshima T. A., Ukita H., Murakami H., Chiba Y., Kamada H., Hara M., Saito I. Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. Oncogene. 1998 Apr 2;16(13):1701–1712. doi: 10.1038/sj.onc.1201691. [DOI] [PubMed] [Google Scholar]
  33. Sherr C. J. Cancer cell cycles. Science. 1996 Dec 6;274(5293):1672–1677. doi: 10.1126/science.274.5293.1672. [DOI] [PubMed] [Google Scholar]
  34. Worsley S. D., Ponder B. A., Davies B. R. Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol. 1997 Feb;64(2):189–195. doi: 10.1006/gyno.1996.4569. [DOI] [PubMed] [Google Scholar]
  35. de Boer C. J., Loyson S., Kluin P. M., Kluin-Nelemans H. C., Schuuring E., van Krieken J. H. Multiple breakpoints within the BCL-1 locus in B-cell lymphoma: rearrangements of the cyclin D1 gene. Cancer Res. 1993 Sep 15;53(18):4148–4152. [PubMed] [Google Scholar]
  36. de Boer C. J., Schuuring E., Dreef E., Peters G., Bartek J., Kluin P. M., van Krieken J. H. Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood. 1995 Oct 1;86(7):2715–2723. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES